Approval · Notice of Compliance 13521 · 2012
RIZATRIPTAN: Notice of Compliance 13521
Issued July 30, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13521
- Date
- July 30, 2012
- Company
- Frosst A Division Of Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- 5-HT1 Receptor Agonist; Migraine Therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIZATRIPTAN | 02390078 | — |
| RIZATRIPTAN | 02390086 | — |
| RIZATRIPTAN RPD | 02390094 | — |
| RIZATRIPTAN RPD | 02390108 | — |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB